Photo by juanster from unsplash
Our group previously demonstrated that 75% of patients with pancreatic ductal adenocarcinoma (PDAC) experienced weight loss in the year preceding diagnosis, and greater prediagnosis weight loss was associated with poor… Click to show full abstract
Our group previously demonstrated that 75% of patients with pancreatic ductal adenocarcinoma (PDAC) experienced weight loss in the year preceding diagnosis, and greater prediagnosis weight loss was associated with poor postoperative outcomes. Unfortunately, nearly all patients with PDAC experience disease recurrence after pancreatectomy. Predictors of recurrence and survival outcomes have been investigated, but few have been validated. Prior studies have investigated postoperative weight change as a prognostic marker but often are limited by small sample sizes, weight measurements at standardized postoperative time points, or short follow-up.
Journal Title: Annals of Surgical Oncology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!